Abbonarsi

Association between transforming growth factor-β1 gene C-509T and T869C polymorphisms and rheumatic heart disease - 26/08/11

Doi : 10.1016/j.ahj.2004.03.032 
Hsiang-Tai Chou, MD, PhD a, , Chien-Hsiun Chen, PhD d, Chang-Hai Tsai, MD, PhD b, Fuu-Jen Tsai, MD, PhD c
a Division of Cardiology, Department of Medicine, China Medical University Hospital, Taichung, Taiwan 
b Taichung Healthcare and Management University, Taichung, Taiwan 
c Department of Pediatrics, Medical Research, and Medical Genetics, China Medical University Hospital and College of Chinese Medicine, China Medical University, Taichung, Taiwan 
d Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan 

*Reprint requests: Hsiang-Tai Chou, MD, PhD, Division of Cardiology, Department of Medicine, China Medical University Hospital, 2 Yuh Der Rd, Taichung 404, Taiwan.

Abstract

Background

Scarring and collagen deposition in the valves and destruction of myocytes may result from the combined effects of a smoldering rheumatic process and a constant trauma to the mitral vlave or aortic valve by the turbulent flow in rheumatic heart disease (RHD). Transforming growth factor-β1 (TGF-β1) may be responsible for the increased valvular fibrosis and calcification in the pathogenesis of RHD. However, the role of TGF-β1 genetic variant in RHD has not been studied. This case-controlled study was carried out to investigate the possible relationship between the TGF-β1 gene C-509T and T869C polymorphisms and RHD among the Chinese population in Taiwan.

Methods

A group of 115 patients with RHD documented by using echocardiography and 100 age- and sex-matched healthy control patients were studied. TGF-β1 gene C-509T and T869C polymorphisms were identified with polymerase chain reaction-based restriction analysis.

Results

A significant difference was seen in the distribution of genotypes between patients with RHD and control patients for either TGF-β1 C-509T polymorphism (P <.0001) or T869C polymorphism (P <.0001). The frequency of TGF-β1 C-509T CC genotype was lower in the RHD group than in the control group (χ2 = 19.05, P <.0001), which suggests that this genotype may confer protective effects against RHD. A significant difference was seen in the distribution of allelic frequency between patients with RHD and control patients for TGF-β1 T869C polymorphism (P = .04). The odds ratio (OR) for risk of RHD associated with TGF-β1 T869C T allele was 1.49 (95% CI, 1.02–2.19). Further categorization of patients with RHD into mitral valve disease and combined valve disease subgroups revealed no statistical difference in these gene polymorphisms when compared with the 2 subgroups.

Conclusions

Patients with RHD have a lower frequency of TGF-β1 C-509T CC genotype and a higher frequency of T869C T allele, which supports a role for the TGF-β1 gene C-509T and T869C polymorphisms in determining the risk/protection of RHD in Taiwan Chinese patients.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2004  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 148 - N° 1

P. 181-186 - luglio 2004 Ritorno al numero
Articolo precedente Articolo precedente
  • Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) Pilot Study
  • Roberto Lorenzoni, Guido Lazzerini, Franca Cocci, Raffaele De Caterina
| Articolo seguente Articolo seguente
  • Information for readers

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.